Showing results (11-20 of 86) with videos related to
Sort By:
Pageof 9
Journal of Medical Economics|April 19, 2021
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatmentAli McBride, Karen MacDonald, Adolfo Fuentes-Alburo, et al.Future Oncology (London, England)|August 23, 2014
Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countriesIvo Abraham, Lucy Han, Diana Sun, et al.Journal of Cardiopulmonary Rehabilitation and Prevention|July 13, 2012
Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statinsJanek Senaratne, Jo Griffiths, Karen MacDonald, et al.Journal of Medical Economics|October 3, 2024
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancerIvo Abraham, Matthias Calamia, Nimer Alkhatib, et al.Journal of Medical Economics|July 17, 2024
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinomaIvo Abraham, Matthias Calamia, Nimer Alkhatib, et al.Clinical Therapeutics|February 24, 2015
Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation studyDiana Sun, Tri Murti Andayani, Ahmed Altyar, et al.Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.Future Oncology (London, England)|September 6, 2017
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzAli McBride, Sanjeev Balu, Kim Campbell, et al.Journal of Medical Economics|July 20, 2017
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaAli McBride, Kim Campbell, Mohan Bikkina, et al.Expert Review of Clinical Immunology|December 14, 2020
'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysisKenneth M Faulkner, Karen MacDonald, Ivo Abraham, et al.Pageof 9